Selexis SA to Showcase Revolutionary Advancements in Protein Expression Technologies at BIO 2014

Selexis to Meet with Biopharmaceutical Companies Interested in Protein Drug Discovery, Mammalian Cell Line Development and Lead Identification for Therapeutic Drug Development and Manufacturing

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
Selexis SURE CHO-Mplus™ Library for difficult-to-express proteins and production bottlenecks

Selexis SURE CHO-Mplus™ Library

The technology addresses issues such as achieving high expression of membrane proteins, secretion bottlenecks with difficult-to-express proteins and development of high-producing clonal cell lines for therapeutic protein production.

Geneva, Switzerland (PRWEB) June 05, 2014

Selexis SA, a serial innovation company with proven technologies for biologic drug discovery and mammalian cell line development, announced today that representatives from the Company will be participating in the BIO International Convention’s One-on-One Partnering Meetings being held June 24 – 26, 2014 at the San Diego Convention Center in San Diego, California. Additionally, the Company’s CEO will present its latest innovation, “CHO Genome Engineering for the Generation of CHO Libraries for Improved Transgene Expression,” at the BioProcess Theater on June 24, 2014 at 2:30 p.m. The BioProcess Theater presentations are part of the Exhibit Hall Specialty Forums during the BIO International Convention.

Selexis has partnerships and commercial deals with leading biotechnology and pharmaceutical companies worldwide. Selexis’ SUREtechnology Platform™ offers a range of solutions for expressing genes in CHO cells and other mammalian systems. The technology addresses issues such as achieving high expression of membrane proteins, secretion bottlenecks with difficult-to-express proteins and development of high-producing clonal cell lines for therapeutic protein production. Selexis’ SUREtechnology Platform™ can be applied from early drug discovery to cGMP manufacturing, resulting in faster, more reliable, higher-expressing mammalian cell lines. This unique and novel platform can be applied to a wide range of areas such as diagnostics, drug discovery, therapeutics and bio-manufacturing.

Representatives will be available to discuss Selexis’ capabilities. Companies or individuals attending BIO 2014 can schedule meetings with Selexis by visiting (registration required): http://convention.bio.org/partner/
For companies or individuals not participating in partnering meetings, Selexis will be exhibiting in booth number #1410 located in Hall A – Bio Process Zone: http://mybio.zerista.com/exhibitor/member/74028?terms=Selexis

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:


Contact

Follow us on: Contact's Facebook Contact's Twitter Contact's LinkedIn

Attachments

.  Selexis’ SUREtechnology Platform™ can be applied from early drug discovery to cGMP manufacturing, resulting in faster, more reliable, higher-expressing mammalian cell lines Selexis

Selexis